Teva Pharmaceutical Industries (TEVA) Deferred Taxes (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Deferred Taxes for 18 consecutive years, with $25.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Deferred Taxes rose 111.85% year-over-year to $25.0 million; the trailing twelve-month figure through Jun 2026 stood at -$485.0 million (down 137.75% YoY), and the FY2025 full-year result was -$671.0 million, down 5.84% from the prior year.
• Deferred Taxes climbed to $25.0 million in Q2 2026 per TEVA's latest filing, from -$22.0 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $150.0 million in Q4 2022 and bottomed at -$1.1 billion in Q2 2022.
• Historically, Deferred Taxes has averaged -$149.1 million across 5 years, with a median of -$48.5 million in 2023.
• The widest YoY moves for Deferred Taxes: up 450.0% in 2022, down 6868.75% in 2022.
• Over 5 years, Deferred Taxes stood at $150.0 million in 2022, then sank by 78.67% to $32.0 million in 2023, then changed by 0.0% to $32.0 million in 2024, then tumbled by 1959.38% to -$595.0 million in 2025, then jumped by 104.2% to $25.0 million in 2026.
• According to Business Quant data, Deferred Taxes over the past three periods registered $25.0 million, -$22.0 million, and -$595.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.